Background {#Sec1}
==========

Persistent high-risk Human Papillomavirus (hr-HPV) infection is the main cause of cervical cancer. However, only 10% of the women infected by hr-HPV develop pre-neoplastic lesions and less than 1% progress to cervical cancer. Only approximately 30% of high-grade cervical lesions progress to uterine cervix cancer, and spontaneous regression occurs in 20--40% of the cases \[[@CR1]--[@CR4]\]. Thus, the risk of cervical carcinogenesis depends on hr-HPV infection and host-dependent features \[[@CR5], [@CR6]\]. Environmental, genetic, and epigenetic cofactors of cervical carcinogenesis has been analyzed as markers for diagnosis, prognosis, and for auxiliary the treatment of pre-neoplastic cervical lesions since they could be predictors of cytological abnormalities remission or persistence \[[@CR7]--[@CR10]\].

Several genetic alterations characterize cervical cancer, such as genomic instability, chromosomal aberration, and the integration of the HPV DNA into the host genome \[[@CR4], [@CR7]\]. These alterations may impact the risk of cervical carcinogenesis substantially. Polymorphism in the genes of enzymes that act on one-carbon metabolism alter their activity and may be associated with cervical carcinogenesis \[[@CR11]--[@CR13]\]. Some of these enzymes are Methylenetetrahydrofolate Reductase (MTHFR), Methionine Synthase (MS), Methionine Synthase Reductase (MTRR), and Thymidylate Synthase (TS).

The MTHFR enzyme, whose gene is located on chromosome 1p36.3, is a flavoprotein that acts on folate metabolism and is essential for DNA integrity \[[@CR14]\]. MTHFR C677T polymorphism consists of the exchange of cytosine (C) for thymine (T) at nucleotide 677. Such polymorphism results in the substitution of Alanine for Valine, which leads to a decrease in MTHFR activity \[[@CR14], [@CR15]\]. This Single Nucleotide Polymorphism (SNP) can change the susceptibility to carcinogenesis by modulating the availability of 5,10-methyleneTHF at different points in folate metabolism \[[@CR16]\].

MS is a vitamin B12-dependent enzyme, essential to the maintenance of intracellular folate levels; it also catalyzes the methylation of homocysteine to methionine \[[@CR17], [@CR18]\]. What causes the MS A2756G polymorphism is the exchange of adenine (A) for guanine (G) at nucleotide 2756 -- which results in the substitution of Aspartic Acid for Glycine, close to the binding domain of vitamin B12 \[[@CR19], [@CR20]\]. Van Der Put et al. (1997) suggested that this SNP affects the secondary structure of MS and has functional consequences. A study has demonstrated the association between the polymorphic allele (G) of MS and the reduction of the number of hypermethylated CpG islands in tumor suppressor genes \[[@CR21]\]. Thus, MS A2756G may alter the activity of tumor suppressor genes, which would explain its association with the development of several types of tumors \[[@CR22]\].

MTRR catalyzes the methylation of vitamin B12, which is a cofactor of MS enzyme \[[@CR23]\]. A66G polymorphism of MTRR enzyme (MTRR A66G) leads to the exchange of A for G in the nucleotide 66. It also leads to the substitution of Isoleucine by Methionine, which results in a decrease of MTRR affinity by MS \[[@CR24]\]. Thus, the polymorphic genotype was negatively associated with homocysteinemia, which alters DNA methylation and, consequently, gene expression \[[@CR23], [@CR25]\].

TS enzyme catalyzes the conversion of deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP), the only de novo source of thymidine for DNA synthesis and repair. TS binds to RNA to repress the translation of its messenger RNA (mRNA) or other proteins and can regulate cell cycle progression \[[@CR26]--[@CR28]\]. Moreover, TS expression is an index of cell proliferation and the biological malignancy of cancer \[[@CR29]\]. The most frequently studied polymorphisms are double or triple 28 bp tandem repeat in 5′-untranslated enhanced region (TSER), and 6 bp deletion/insertion at nucleotide 1494 in TS 3′-untranslated region (TS3'UTR). These two genetic variations may influence the TS gene expression and the stability of its mRNA, respectively \[[@CR28]\].

Alterations in the one-carbon metabolism compromise the integrity of genetic material. Such compromise is due to changes in the nucleotide pool and uracil incorporation, which leads to DNA instability. Besides, global hypomethylation and site-specific hypermethylation are observed, which lead to the activation of proto-oncogenes and silencing of tumor suppressor genes \[[@CR10], [@CR30], [@CR31]\].

Therefore, the aim of this study was to evaluat the risk of persistence of pre-neoplastic cervical lesions according to genetic polymorphisms involved in one-carbon metabolism.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Two hundred and eighty women were selected for this study between October 2016 and September 2018. They all lived in Minas Gerais State and attended the Basic Health Units of Ouro Preto and State Specialized Care Center of Itabirito. To be included in the study, their age should be at least 18 years. We excluded women who had been pregnant within the last 6 months, had a history of neoplasia, or the presence of cervical atypia in glandular cells.

At the first meeting (T~1~), we interviewed them to get sociodemographic and behavioral information. We also collected a cervical sample for cytological analysis, genetic polymorphism evaluation, and HPV detection. After 6 months of follow-up (T~2~), 164 women performed the second cytological analysis. A total of 58 participants were excluded: 50 who presented normal cytology at T~1~ and T~2~, and eight who presented normal cytology at T~1~ and pre-neoplastic lesion at T~2~ (Fig. [1](#Fig1){ref-type="fig"}). We divided the resulting sample group (*n* = 106) into: Remission (*n* = 60): presence of pre-neoplastic lesion at T~1~, and normal cytology at T~2~, out of which;45.0% (*n* = 27) presented Atypical Squamous Cells of Undetermined Significance (ASC-US) at T~1~;35.0% (*n* = 21) presented Low-Grade Squamous Intraepithelial Lesion (LSIL) at T~1~;15.0% (*n* = 9) presented High-Grade Squamous Intraepithelial Lesion (HSIL) at T~1~.5.0% (*n* = 3) presented Atypical Squamous Cell -- cannot exclude HSIL (ASC-H) at T~1~;Persistence (*n* = 46): presence of pre-neoplastic lesion at T~1~ and T~2~:69.7% (*n* = 32) presented the same cervical lesion at T~1~ and T~2~:ASC-US at T~1~ and T~2~ (*n* = 8, 25.0%);LSIL at T~1~ and T~2~ (*n* = 9, 28.1%);ASC-H at T~1~ and T~2~ (*n* = 7, 21.9%);HSIL at T~1~ and T~2~ (*n* = 8, 25%).b.23.9% (*n* = 11) presented LSIL at T~1~ and ASC-US at T~2~;c.6.4% (*n* = 3) presented LSIL or ASC-US at T~1~ and ASC-H at T~2~.Fig. 1Study flow diagram

T~1~: First meeting; T~2~: Second meeting; Remission: Presence of pre-neoplastic cervical lesion at T~1~, and normal cytology at T~2~; Persistence: Pre-neoplastic cervical lesion detected at T~1~ and T~2~.

We considered the presence of pre-neoplastic lesions when ASC-US, LSIL, HSIL, or ASC-H were detected. Also, as stated before, we only considered the Remission and Persistence groups for statistical analyses, not differentiating the types of cytological abnormalities.

The Research Ethics Committee of the Federal University of Ouro Preto approved this study (CAAE 57187316.7.0000.5150, and CAAE 88479718.0.0000.5150).

Sample collection {#Sec4}
-----------------

Health care professionals obtained cervical samples through the conventional double collection, using Ayre spatulas for the ectocervical sample, and cylindrical brushes for the endocervical sample. After the confection of cervical smear for cytological analysis, the brush was conditioned in Phosphate-Buffered Saline (PBS) pH 7.2 and stored at − 80 °C for the evaluation of genetic polymorphisms.

Cytological analysis {#Sec5}
--------------------

Cervical smears were stained according to the Papanicolaou method, and samples were evaluated based on cytomorphological criteria described in Bethesda System 2014 for reporting cervical cytological diagnoses (Nayar and Wilbur, 2015). Two cytopathologists evaluated all the samples. In the case of different results, a third professional evaluated the sample. The analyses were performed at the Laboratório de Análises Clínicas (LAPAC) from the Federal University of Ouro Preto.

DNA extraction {#Sec6}
--------------

DNA was extracted from the cervical samples with illustra blood genomicPrep Mini Spin™ Kit (GE Healthcare, Chicago, Illinois, USA). The evaluation of the quality and integrity of DNA was performed by amplification of the *β-actin* gene \[[@CR32]\].

HPV detection {#Sec7}
-------------

HPV detection was performed by conventional Polymerase Chain Reaction (PCR) with MY09/MY11 primers, as described by Miranda et al. (2013). For positive samples, the HPV genotype was analyzed by Restriction Fragment Length Polymorphism (RFLP) \[[@CR32]\]. HPV-negative samples were also analyzed by conventional PCR with GP5+/GP6+ primers \[[@CR33]\].

Genetic polymorphisms {#Sec8}
---------------------

MTHFR C677T (rs1801133), MS A2756G (rs1805087), MTRR A66G (rs1801394), and TS3'UTR (rs151264360) polymorphisms were evaluated by PCR-RFLP \[[@CR14], [@CR34]--[@CR36]\]. TSER (rs34743033) was evaluated by PCR \[[@CR37]\].

Sequences of primers, restriction enzymes, and PCR protocols are shown in *Supplementary Tables* [*1*](#MOESM1){ref-type="media"}*,*[*2*](#MOESM1){ref-type="media"}*, and*[*3*](#MOESM1){ref-type="media"}. Table [1](#Tab1){ref-type="table"} shows the size of the DNA fragments that characterize the genotypes of the polymorphisms analyzed. Table 1Size of DNA fragments for genetic polymorphisms analysisGenetic polymorphismsGenotypesNo polymorphicHeterozygotePolymorphicMTHFR C677T198 bp23 bp, 175 bp and 198 bp175 bp and 198 bpMS A2756G211 bp80 bp, 131 bp and 211 bp80 bp and 131 bpMTRR A66G22 bp and 44 bp22 bp, 44 bp and 66 bp66 bpTS3'UTR70 bp and 88 bp70 bp, 88 bp and 152 bp152 bpTSER220 bp220 bp and 248 bp248 bp

GRS was calculated to evaluate the presence of all polymorphisms simultaneously, as described by Tomita et al. (2013). The presence of heterozygosity received one point; the presence of polymorphic homozygotes received two points. Non-polymorphic homozygotes were not scored (zero) \[[@CR13]\]. Thus, the higher the GRS, the higher the frequency of genetic polymorphisms.

Statistical analysis {#Sec9}
--------------------

Data were tabulated by Microsoft Office Excel™ (Microsoft, Redmond, Washington, USA), and analyzed by Statistical Package for the Social Sciences™ 17.0 (International Business Machines, New York, USA).

To evaluate the frequency of genotypes, we performed descriptive statistics. The allelic frequency was calculated by Genepop software \[[@CR38]\]. HWE of genotypic frequencies was calculated by the HWE calculator, including analysis for ascertainment bias \[[@CR39]\]. To compare the groups, we used the Chi-square. Also, we used binary logistic regression to calculate the relative risk (Odds Ratio) with a 95% confidence interval.

*p* values \< 0.05 were considered evidence of statistically significant association.

Results {#Sec10}
=======

To evaluate the association between genetic polymorphisms in enzymes involved in folate metabolism with cervical carcinogenesis, we analyzed samples of 106 women with remission or persistence of cytological abnormalities. We also evaluated sociodemographic and behavioral characteristics such as age, education, use of alcohol, smoking, marital status, information about sexual life, pregnancies, and use of hormonal contraceptives. These characteristics can be considered cofactors of cervical cancer \[[@CR5], [@CR8], [@CR10], [@CR40]\].

The mean age of participants was 39.7 ± 11.4 years, ranging from 19 to 71 years, and 32.1% (*n* = 34) were between 35 and 44 years. Most women resided in urban areas (*n* = 97, 91.5%), had family financial income \<US\$250/month (*n* = 70, 74.5%), high school education (*n* = 46, 47.9%), were non-smokers (*n* = 81, 84.4%), and ingested alcoholic beverages (*n* = 57, 59.4%).

Most of the women reported being married or having a fixed partner (*n* = 77, 80.2%), having had the first sexual intercourse at the age of 18 years or older (*n* = 53, 56.4%), and three or more sexual partners (*n* = 55, 57.3%). Also, most of them did not use hormonal contraceptives (*n* = 61, 63.5%) and had already been pregnant (*n* = 81, 84.4%) (Table [2](#Tab2){ref-type="table"}). We observed these characteristics at a similar rate and with no significant association (*p* \< 0.05) among the Remission and Persistence groups (Table [2](#Tab2){ref-type="table"}). Table 2Sociodemographic and behavioral characteristicsCharacteristicsCytological abnormalityTotal\
n (%)Remission\
n (%)Persistence\
n (%)pAge (years)  \< 2512 (11.3)7 (11.7)5 (10.9)0.302 25--3421 (19.8)9 (15.0)12 (26.1) 35--4434 (32.1)18 (30.0)16 (34.8) 45--5428 (26.4)17 (28.3)11 (23.9)  ≥ 5511 (10.4)9 (15.0)2 (4.3)Area Urban97 (91.5)54 (90.0)43 (93.5)0.524 Countryside9 (8.5)6 (10.0)3 (6.5)Income per person (US\$/month)^1^  \< 25070 (74.5)40 (72.7)30 (76.9) 250--50021 (22.3)12 (21.8)9 (23.1)0.333  ≥ 5003 (3.2)3 (5.5)0Education^2^ Elementary school/Illiterate44 (45.8)23 (41.8)21 (51.2)0.341 High school46 (47.9)27 (49.1)19 (46.3) University6 (6.3)5 (9.1)1 (2.4)Smoker^2^ No81 (84.4)48 (87.3)33 (80.5)0.365 Yes^a^15 (15.6)7 (12.7)8 (19.5)Use of alcoholic beverage^2^ No39 (40.6)22 (40.0)17 (41.5)0.885 Yes^a^57 (59.4)33 (60.0)24 (58.5)Marital status^2^ Married/Fixed Partner77 (80.2)40 (72.7)37 (90.2)0.073 Single9 (9.4)8 (14.5)1 (2.4) Widow/Divorced10 (10.4)7 (12.7)3 (7.3)Age at first vaginal intercourse (years)^1^  \< 1841 (43.6)25 (45.5)16 (41.0)0.670  ≥ 1853 (56.4)30 (54.5)23 (59.0)Lifetime sexual partners^2^ 123 (23.9)13 (23.6)10 (24.4)0.936 218 (18.8)11 (20.0)7 (17.1)  ≥ 355 (57.3)31 (56.4)24 (58.5)Use of hormonal contraceptive^2^ No61 (63.5)39 (70.9)22 (53.7)0.082 Yes35 (36.5)16 (29.1)19 (46.3)Pregnancies^2^ 015 (15.6)9 (16.4)6 (14.6)0.130 119 (19.8)14 (25.5)5 (12.2) 226 (27.1)10 (18.2)16 (39.0) 322 (22.9)12 (21.8)10 (24.4)  ≥ 414 (14.6)10 (18.2)4 (9.8)HPV infection52 (49.1)Negative54 (50.9)37 (61.7)15 (32.6)0.003Positive23 (38.3)31 (67.4)

Concerning HPV, the main factor for cervical carcinogenesis \[[@CR3]\], 50.9% (*n* = 54) of the participants were infected. The infection rate was higher in the Persistence group (*n* = 31, 67.4%) than in the Remission group (*n* = 23, 38.3%) (*p* = 0.003). We obtained similar results with the analysis of hr-HPV infection alone (*p* = 0.000) (data not shown).

Participants excluded due to absence of information: ^1^Twelve; ^2^Ten. ^a^Amount or frequency not determined. Remission: presence of pre-neoplastic lesion at T~1~, and normal cytology at T~2~; Persistence: pre-neoplastic lesion detected at T~1~ and T~2~.

Regarding the genetic polymorphisms evaluated, MTRR A66G genotypic frequencies were 10.4% (*n* = 11), 76.4% (*n* = 81), and 13.2% (*n* = 14) of AA, AG, and GG, respectively. The genotypic frequency of TSER was 35.8% (*n* = 38) of 2R/2R, 31.1% (*n* = 33) of 2R/3R, and 33.0% (*n* = 35) of 3R/3R. However, we could not find the distribution of genotypes of MTRR A66G and TSER of the Remission group under Hardy-Weinberg equilibrium (*p* = 0.000). Thus, these polymorphisms were excluded from further analyses in this study.

MTHFR C677T genotypic frequencies were 50.0% (*n* = 53) of CC, 45.3% (*n* = 48) of CT, and 4.7% (*n* = 5) of TT; the T allelic frequency was 27.4%. We detected the MS A2756G polymorphic genotype in 3.8% (*n* = 4) of the samples, and G allele in 19.8%. On the other hand, a higher frequency of women presented polymorphic genotype for TS3'UTR genetic variation (16.0%, *n* = 17), and the frequency of del allelic was 41.5% (Table [3](#Tab3){ref-type="table"}). Table 3Frequencies of genetic polymorphisms according Remission or Persistence of pre-neoplastic cervical lesionsGenetic polymorphismsCytological abnormalityTotalRemission\
(*n* = 60)Persistence\
(*n* = 46)OR (IC95%)^a^pMTHFR C677T^1^*Genotype n (%)*  CC53 (50.0)28 (46.7)25 (54.3)1.0  CT48 (45.3)28 (46.7)20 (43.5)0.93 (0.40--2.12)0.856  TT5 (2.2)4 (6.6)1 (2.2)0.25 (0.02--2.48)0.245*Allele %*  C72.670.076.11.0  T27.430.023.90.71 (0.34--2.11)0.842MS A2756G^2^*Genotype n (%)*  AA69 (65.4)42 (70.0)27 (58.7)1.0  AG33 (31.1)17 (28.3)16 (34.8)1.20 (0.50--2.89)0.690  GG4 (3.8)1 (1.7)3 (6.5)4.99 (0.46--54.57)0.188*Allele %*  A80.283.376.11.0  G19.816.723.91.63 (0.59--4.53)0.349TS3'UTR^3^*Genotype n (%)*  ins/ins34 (32.1)26 (43.3)8 (17.4)1.0  ins/del55 (51.9)28 (46.7)27 (58.7)3.22 (1.19--8.69)0.021  del/del17 (16.0)6 (10.0)11 (23.9)6.50 (1.71--24,70)0.006*Allele %*  ins58.566.747.81.0  del41.533.352.22.28 (1.00--5.22)0.051GRS n(%)  ≤ 277 (72.6)48 (80.0)29 (63.0)1.00  ≥ 329 (27.4)12 (20.0)17 (37.0)2.21 (0.89--5.48)0.086

Hardy-Weinberg Equilibrium (HWE): ^1^p = 0.389; ^2^p = 0.625; ^3^p = 0.699. ^a^Adjusted for HPV infection. Remission: presence of pre-neoplastic lesion at T~1~, and normal cytology at T~2~; Persistence: pre-neoplastic lesion detected at T~1~ and T~2~.

To evaluate the association between the MTHFR C677T, MS A2756G, and TS3'UTR polymorphisms according to the course of cytological abnormalities, we compared the genotype distribution of the Remission and Persistence groups (Table [3](#Tab3){ref-type="table"}).

There were no differences in the distribution of MTHFR C677T and MS A2756G and the course of cytological abnormalities (Table [3](#Tab3){ref-type="table"}). On the other hand, women with persistent lesions had higher heterozygote and polymorphic genotypic frequencies of TS3'UTR than those from the Remission group. Furthermore, the ins/del and del/del genotypes increased the risk of persistence at least three times \[OR (IC95%): 3.13 (1.21--8.12), *p* = 0.019; OR (IC95%): 5.96 (1.67--21.25), *p* = 0.006 - respectively\] (Table [3](#Tab3){ref-type="table"}).

To simultaneously evaluate the presence of MTHFR C677T, MS A2756G, and TS3'UTR, we determined the Genetic Risk Score (GRS) \[[@CR13]\]. A score of ≥3 meant a high number of genetic variants. GRS ≥ 3 was more frequent in the Persistence group (*n* = 17, 37.0%) than in the Remission group (*n* = 12, 20.0%). Also, a high number of genetic variants presented higher risk of persistent lesions \[OR (IC95%): 2.21 (0.89--5.48), *p* = 0.086\] (Table [3](#Tab3){ref-type="table"}). However, when adjusted for TS3'UTR, the risk of persistence according GRS was modified \[OR (IC 95%): 1.26 (0.44--3.61), *p* = 0.669\], showing that, between the three polymorphisms analyzed, only TS3'UTR was associated with the course of cytological abnormality.

Discussion {#Sec11}
==========

Although persistent hr-HPV infection is the main cause of cervical cancer development, genetic alterations may impact on the risk of this neoplasia. Thus, genetic markers may be useful in the screening of pre-neoplastic and neoplastic cervical lesions, especially in cases of persistent HPV infections or recurrent cytological abnormalities \[[@CR7], [@CR41]\]. Moreover, the conventional methods used for screening cervical cancer cannot differentiate pre-neoplastic cervical lesions that will regress or persist and progress. Therefore, the prognosis of individual pre-neoplastic lesions should be predictable, to select women with a higher risk of persistence and progression, which could decrease the number of unnecessary treatment of lesions \[[@CR4]\].

In this study, we evaluated five genetic polymorphisms in enzymes that act on one-carbon metabolism: MTHFR C677T, MS A2756G, MTRR A66G, TSER, and TS3'UTR. However, the distributions of MTRR A66G and TSER were not under Hardy-Weinberg Equilibrium (HWE), which led to their exclusion from further analyses. Other studies with the Brazilian population did not present a genotypic distribution of these polymorphisms under HWE either \[[@CR42], [@CR43]\].

Many polymorphisms were identified in the TS gene, located on chromosome 18p11.32. One of the most frequently studied polymorphisms is TS3'UTR, related to an increased in vitro degradation of its mRNA, which led to a decrease of expression protein \[[@CR36]\]. The presence of the polymorphic allele (del) of TS3'UTR doubled the risk of persistence of cytological abnormalities. It was probably due to decreased synthesis of thymidylate, catalyzed by the TS enzyme. This enzyme's activity is decreased by TS3'UTR polymorphism, and, as a result, DNA uracil is incorporated. The consequence of that is DNA instability and chromosome damage, crucial for carcinogenesis \[[@CR26], [@CR36], [@CR44]\].

The integration of the HPV genome and the DNA of the host cell is probably one of the decisive steps for oncogenesis. It occurs preferentially in transcriptionally active regions, close to fragile DNA sites, and is observed in most invasive cancers \[[@CR45]\]. Also, the HPV genome is integrated with chromosomes in some low-grade lesions and in most high-grade lesions \[[@CR46], [@CR47]\].

On the other hand, although the MTHFR C677T and MS A2756G polymorphisms have already been associated with pre-neoplastic and neoplastic lesions in the uterine cervix, we did not observe any association of these SNPs with the persistence of cytological abnormalities \[[@CR11], [@CR13]\].

The limitations of this study were the small sample size, the loss of participants during the study, and the short follow-up time. To better understand the role of genetic cofactors on cervical carcinogenesis, it is necessary to carry out more extensive studies, for a more extended period, and with different population groups. Besides, one should also consider different grades of cytological abnormalities separately.

In this study, we only considered the Remission and Persistence groups for statistical analyses due to the small number of samples of each subgroup. Still, analyzing these subgroups separately, there was no significant difference in genotypic or allelic frequencies of the evaluated polymorphisms (data not shown).

Nevertheless, this was the first study to evaluate the link between the risk of persistence of pre-neoplastic cervical lesions and the presence of genetic polymorphisms in enzymes that act on folate metabolism. Some authors have shown an association between the TS3'UTR polymorphism and esophageal, gastric, and breast cancers, although the results were controversial and varied with ethnicity \[[@CR48]--[@CR52]\]. However, studies on this polymorphism as a marker of cervical carcinogenesis have shown promising results, and further investigations are needed.

Conclusions {#Sec12}
===========

The presence of the TS3'UTR polymorphism increased the risk of cervical abnormalities persistence. Thus, this genetic variant could be a potential marker of cervical carcinogenesis, which would assist the follow-up of women with persistent pre-neoplastic cervical lesions.
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 {#Sec13}

**Additional file 1: Table S1.** Sequences of primers, and restrictions enzymes used for analysis of genetic polymorphisms. **Table S2.** PCR protocol used for analysis of genetic polymorphisms. **Table S3.** Reagents for analysis of genetic polymorphisms by PCR.

A

:   Adenine

ASC-H

:   Atypical Squamous Cell -- cannot exclude High Grade Squamous Intraepithelial Lesion

ASC-US

:   Atypical Squamous Cells of Undetermined Significance

C

:   Cytosine

dTMP

:   deoxythymidine monophosphate

dUMP

:   deoxyuridine monophosphate

G

:   Guanine

GRS

:   Genetic Risk Score

HPV

:   Human Papillomavirus

hr-HPV

:   high-risk Human Papillomavirus

HSIL

:   High Grade Squamous Intraepithelial Lesion

HWE

:   Hardy-Weinberg Equilibrium

LAPAC

:   Laboratório de Análises Clínicas

LSIL

:   Low Grade Squamous Intraepithelial Lesion

mRNA

:   messenger RNA

MS

:   Methionine Synthase

MS A2756G

:   polymorphism A2756G of Methionine Synthase

MTHFR

:   Methylenetetrahydrofolate Reductase

MTHFR C677T

:   polymorphism C667T of Methylenetetrahydrofolate Reductase

MTRR

:   Methionine Synthase Reductase

MTRR A66G

:   Polymorphism A66G of Methionine Synthase Reductase

PBS

:   Phosphate-Buffered Saline

PCR

:   Polymerase Chain Reaction

RFLP

:   Restriction Fragment Length Polymorphism

SNP

:   Single Nucleotide Polymorphism

T

:   Thymine

T~1~

:   First meeting

T~2~

:   Second meeting, after 6 months of follow-up

TS

:   Thymidylate Synthase

TS3'UTR

:   6 bp deletion at nucleotide1494 in TS 3′-untranslated region

TSER

:   Double or triple 28 bp tandem repeat in 5′-untranslated enhanced region of Thymidylate Synthase
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